109 related articles for article (PubMed ID: 21632639)
1. Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.
Glass JP; Parasher G; Arias-Pulido H; Donohue R; Prossnitz ER; Cerilli LA
Int J Surg Pathol; 2011 Oct; 19(5):588-96. PubMed ID: 21632639
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
3. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.
McCarthy DM; Maitra A; Argani P; Rader AE; Faigel DO; Van Heek NT; Hruban RH; Wilentz RE
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):238-43. PubMed ID: 12966350
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.
Ino Y; Akimoto T; Takasawa A; Takasawa K; Aoyama T; Ueda A; Ota M; Magara K; Tagami Y; Murata M; Hasegawa T; Saito T; Sawada N; Osanai M
Histol Histopathol; 2020 Apr; 35(4):351-359. PubMed ID: 31483053
[TBL] [Abstract][Full Text] [Related]
5. [Expression and diagnostic value of mesothelin in specimen of pancreas fine-needle aspiration].
Zhu QY; Li ZS; Pan X; Sun ZX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):615-8. PubMed ID: 16274044
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
Baruch AC; Wang H; Staerkel GA; Evans DB; Hwang RF; Krishnamurthy S
Diagn Cytopathol; 2007 Mar; 35(3):143-7. PubMed ID: 17304533
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.
Jhala N; Jhala D; Vickers SM; Eltoum I; Batra SK; Manne U; Eloubeidi M; Jones JJ; Grizzle WE
Am J Clin Pathol; 2006 Oct; 126(4):572-9. PubMed ID: 17019794
[TBL] [Abstract][Full Text] [Related]
8. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
Cao D; Maitra A; Saavedra JA; Klimstra DS; Adsay NV; Hruban RH
Mod Pathol; 2005 Jun; 18(6):752-61. PubMed ID: 15696124
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration.
Dim DC; Jiang F; Qiu Q; Li T; Darwin P; Rodgers WH; Peng HQ
Diagn Cytopathol; 2014 Mar; 42(3):193-9. PubMed ID: 21538952
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
[TBL] [Abstract][Full Text] [Related]
11. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.
Filardo EJ; Graeber CT; Quinn JA; Resnick MB; Giri D; DeLellis RA; Steinhoff MM; Sabo E
Clin Cancer Res; 2006 Nov; 12(21):6359-66. PubMed ID: 17085646
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Einama T; Kamachi H; Nishihara H; Homma S; Kanno H; Takahashi K; Sasaki A; Tahara M; Okada K; Muraoka S; Kamiyama T; Matsuno Y; Ozaki M; Todo S
Pancreas; 2011 Nov; 40(8):1276-82. PubMed ID: 21775916
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
15. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
Cao D; Ji H; Ronnett BM
Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Hornick JL; Lauwers GY; Odze RD
Am J Surg Pathol; 2005 Mar; 29(3):381-9. PubMed ID: 15725808
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
Argani P; Iacobuzio-Donahue C; Ryu B; Rosty C; Goggins M; Wilentz RE; Murugesan SR; Leach SD; Jaffee E; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Clin Cancer Res; 2001 Dec; 7(12):3862-8. PubMed ID: 11751476
[TBL] [Abstract][Full Text] [Related]
18. GPR30: a novel indicator of poor survival for endometrial carcinoma.
Smith HO; Leslie KK; Singh M; Qualls CR; Revankar CM; Joste NE; Prossnitz ER
Am J Obstet Gynecol; 2007 Apr; 196(4):386.e1-9; discussion 386.e9-11. PubMed ID: 17403429
[TBL] [Abstract][Full Text] [Related]
19. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
20. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
